Clinical Relevance of Sarcopenia in Individuals with COPD: A Systematic Review and Meta-Analysis

Probst, VS; Sepúlveda-Loyola, Walter; Osadnik, Christian; Phu, Steven; Morita, A.A.; Galvan, Carrie Chueiri Ramos; Felcar, Josiane Marques; Duque, Gustavo

doi:10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a7382

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sarcopenia is associated with several human health conditions, such as cardiac disease [ 6 , 7 , 8 ], respiratory disease [ 9 , 10 , 11 ], osteoporosis [ 12 , 13 , 14 ], depression [ 15 , 16 ], renal function [ 17 , 18 , 19 , 20 ], and liver cirrhosis [ 21 , 22 ]. Sarcopenia in cancer patients is being actively investigated because it is an important factor in the quality of life, hospitalization time, chemotherapy-induced toxicity, postoperative complications, depressive mood, and overall survival [ 23 , 24 , 25 , 26 ].…”

Section: Introductionmentioning

confidence: 99%

Clinical Impact of Sarcopenia on Cholangiocarcinoma

Shin

Koh

2022

Life

View full text Add to dashboard Cite

Sarcopenia is considered an important factor affecting the prognosis of cancer patients. Only complete surgical resection confers the chance of curing cholangiocarcinoma with sarcopenia. However, the prognosis is poor, even for patients who undergo surgical resection. Data from 13 trials of patients with sarcopenia and intrahepatic cholangiocarcinoma (ICC) or perihilar cholangiocarcinoma (PHC) were collected and reviewed. During all trials, sarcopenia was assessed using the psoas muscle or total skeletal muscle at the L3 level on cross-sectional images. The data showed heterogeneity among the subjects and treatment options and discrepancies in methods of measuring muscle mass and setting the cut-off level. Despite conflicting results regarding morbidity, mortality, and recurrence, sarcopenia may be associated with poor overall survival and recurrence-free survival (RFS) for ICC patients. The impact of sarcopenia on the morbidity of ICC patients remains unclear. The impact of PHC on morbidity, mortality, and RFS is also unclear. Further well-designed studies are needed to elucidate the effects of sarcopenia on ICC and PHC.

show abstract